{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:21:04Z","timestamp":1793604064172,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This meta-analysis aimed to determine the pooled association between polycystic ovary syndrome (PCOS), hypothyroidism, and fibrocystic breast changes. We searched important databases, including PubMed (Medline), Scopus, Web of Science, and Embase to retrieve all relevant studies published from 1990 to April 2021. The bias risk of selected articles was assessed based on the JBI checklist. Our search strategy yielded a total of 487 articles from the international databases. After screening their full-texts, 6 articles met the inclusion criteria and were considered for meta-analysis. The effect of PCOS on the incidence of fibrocystic breast changes was 2.49 (95% CI 1.85\u20133.34). Also, the effect of hypothyroidism on the incidence of fibrocystic breast changes was 1.90 (95% CI 0.92\u20133.93). The results showed that women with PCOS were at higher risks to develop fibrocystic breast changes.<\/jats:p>","DOI":"10.1186\/s12935-022-02547-5","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:03:22Z","timestamp":1647691402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Parisa","family":"Kohnepoushi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojat","family":"Dehghanbanadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Mohammadzedeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maziar","family":"Nikouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-5930","authenticated-orcid":false,"given":"Yousef","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"1","key":"2547_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0015-0282(00)01662-9","volume":"75","author":"MD Kahsar-Miller","year":"2001","unstructured":"Kahsar-Miller MD, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75(1):53\u20138.","journal-title":"Fertil Steril"},{"issue":"5","key":"2547_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467\u2013520.","journal-title":"Endocr Rev"},{"key":"2547_CR3","doi-asserted-by":"crossref","unstructured":"Dewailly D, et al. Polycystic ovary syndrome (PCOS). In: Annales D'endocrinologie. 2010. Elsevier.","DOI":"10.1016\/j.ando.2009.12.003"},{"issue":"3","key":"2547_CR4","doi-asserted-by":"publisher","first-page":"E480","DOI":"10.1210\/jc.2010-1658","volume":"96","author":"E Kandaraki","year":"2011","unstructured":"Kandaraki E, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011;96(3):E480\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2547_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6\u201315.","journal-title":"Fertil Steril"},{"key":"2547_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.gene.2019.04.082","volume":"706","author":"B Chen","year":"2019","unstructured":"Chen B, et al. The role of MiRNA in polycystic ovary syndrome (PCOS). Gene. 2019;706:91\u20136.","journal-title":"Gene"},{"issue":"11","key":"2547_CR7","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1093\/humrep\/der297","volume":"26","author":"D Dewailly","year":"2011","unstructured":"Dewailly D, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123\u20139.","journal-title":"Hum Reprod"},{"issue":"4","key":"2547_CR8","first-page":"529","volume":"93","author":"M Liu","year":"2020","unstructured":"Liu M, Murthi S, Poretsky L. Focus: sex & reproduction: polycystic ovary syndrome and gender identity. Yale J Biol Med. 2020;93(4):529.","journal-title":"Yale J Biol Med"},{"key":"2547_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-4757-3906-0_14","volume":"15","author":"A Dunaif","year":"1997","unstructured":"Dunaif A, Book CB. Insulin resistance in the polycystic ovary syndrome. Clin Res Diabetes Obes. 1997;15:249\u201374.","journal-title":"Clin Res Diabetes Obes"},{"key":"2547_CR10","first-page":"377","volume-title":"Diagnostic criteria for PCOS: towards a more rational approach. PCOS","author":"J Zawadeski","year":"1992","unstructured":"Zawadeski J, Dunaif A. Diagnostic criteria for PCOS: towards a more rational approach. PCOS. Boston: Blackwell Scientific; 1992. p. 377\u201384."},{"issue":"1","key":"2547_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137.","journal-title":"Hum Reprod"},{"issue":"1","key":"2547_CR12","first-page":"17","volume":"18","author":"MB Mohammad","year":"2017","unstructured":"Mohammad MB, Seghinsara AM. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev. 2017;18(1):17.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"2547_CR13","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2547_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1055\/a-1392-0938","volume":"53","author":"M Kunicki","year":"2021","unstructured":"Kunicki M, Smolarczyk R. Polycystic ovary syndrome and fibrocystic breast disease: an updated review. Horm Metab Res. 2021;53(4):219\u201324.","journal-title":"Horm Metab Res"},{"issue":"1","key":"2547_CR15","first-page":"1","volume":"8","author":"Y-Y Chen","year":"2018","unstructured":"Chen Y-Y, et al. Examining the associations among fibrocystic breast change, total lean mass, and percent body fat. Sci Rep. 2018;8(1):1\u20136.","journal-title":"Sci Rep"},{"issue":"3","key":"2547_CR16","first-page":"383","volume":"4","author":"ND Gungor","year":"2020","unstructured":"Gungor ND, G\u00fcrb\u00fcz T, Ok\u00e7u NT. Correlation between HbA1c and fibrocystic breast disease among polycystic ovary syndrome. Cumhuriyet Med J. 2020;4(3):383.","journal-title":"Cumhuriyet Med J"},{"issue":"7","key":"2547_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1742-1241.2005.00417.x","volume":"59","author":"A Soran","year":"2005","unstructured":"Soran A, et al. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract. 2005;59(7):795\u20137.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2547_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00404-008-0889-8","volume":"280","author":"II Gumus","year":"2009","unstructured":"Gumus II, et al. Polycystic ovary syndrome and fibrocystic breast disease: is there any association? Arch Gynecol Obstet. 2009;280(2):249\u201353.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2547_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000052909","volume":"51","author":"R D\u2019Amelio","year":"2001","unstructured":"D\u2019Amelio R, et al. Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest. 2001;51(2):134\u20137.","journal-title":"Gynecol Obstet Invest"},{"issue":"3","key":"2547_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5152\/imj.2018.44452","volume":"19","author":"S Alipour","year":"2018","unstructured":"Alipour S, Shirzad N, Saberi A, Seifollahi A, Rastad H, Hosseini L. Association of benign breast disorders with hypothyroidism. Istanbul Med J. 2018;19(3):246\u201350.","journal-title":"Istanbul Med J."},{"issue":"9","key":"2547_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40618-015-0269-8","volume":"38","author":"C Anil","year":"2015","unstructured":"Anil C, Guney T, Gursoy A. The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto\u2019s thyroiditis. J Endocrinol Invest. 2015;38(9):971\u20135.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2547_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41182-018-0133-6","volume":"47","author":"GM Tawfik","year":"2019","unstructured":"Tawfik GM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1):1\u20139.","journal-title":"Trop Med Health"},{"issue":"7","key":"2547_CR23","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"2547_CR24","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"issue":"8","key":"2547_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/oxfordjournals.aje.a116156","volume":"134","author":"MD Gammon","year":"1991","unstructured":"Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol. 1991;134(8):818\u201324.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2547_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5468\/ogs.2016.59.5.367","volume":"59","author":"F Shobeiri","year":"2016","unstructured":"Shobeiri F, Jenabi E. The association between polycystic ovary syndrome and breast cancer: a meta-analysis. Obstet Gynecol Sci. 2016;59(5):367\u201372.","journal-title":"Obstet Gynecol Sci"},{"issue":"8","key":"2547_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.steroids.2013.04.004","volume":"78","author":"DA Dumesic","year":"2013","unstructured":"Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782\u20135.","journal-title":"Steroids"},{"issue":"1","key":"2547_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40738-016-0029-2","volume":"2","author":"HR Harris","year":"2016","unstructured":"Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2(1):1\u20139.","journal-title":"Fertil Res Pract"},{"issue":"3","key":"2547_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10552-016-0716-7","volume":"27","author":"J Kim","year":"2016","unstructured":"Kim J, et al. Polycystic ovarian syndrome (PCOS), related symptoms\/sequelae, and breast cancer risk in a population-based case\u2013control study. Cancer Causes Control. 2016;27(3):403\u201314.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"2547_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/humupd\/7.6.522","volume":"7","author":"A Balen","year":"2001","unstructured":"Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7(6):522\u20135.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"2547_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajog.2021.03.020","volume":"225","author":"T Zhu","year":"2021","unstructured":"Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and breast cancer subtypes: a Mendelian randomization study. Am J Obstet Gynecol. 2021;225(1):99\u2013101.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2547_CR32","doi-asserted-by":"publisher","first-page":"e899","DOI":"10.1210\/clinem\/dgab757","volume":"107","author":"T Zhu","year":"2021","unstructured":"Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization. J Clin Endocrinol Metab. 2021;107(3):e899\u2013911.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2547_CR33","first-page":"990","volume":"81","author":"C Giani","year":"1996","unstructured":"Giani C, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab. 1996;81(3):990\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2547_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/thy.2014.0331","volume":"25","author":"AM Leung","year":"2015","unstructured":"Leung AM, et al. Potential risks of excess iodine ingestion and exposure: statement by the American Thyroid Association Public Health Committee. Thyroid. 2015;25(2):145\u20136.","journal-title":"Thyroid"},{"issue":"10","key":"2547_CR35","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00268-009-0143-y","volume":"33","author":"PR Bhargav","year":"2009","unstructured":"Bhargav PR, et al. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg. 2009;33(10):2087\u201393.","journal-title":"World J Surg"},{"issue":"4","key":"2547_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5455\/jmood.20161122123332","volume":"6","author":"SF Qureshi","year":"2016","unstructured":"Qureshi SF, Siddiqui JA, Shawosh YBA. Chlorpromazine-induced hyperprolactinemia in a young female and its relation with fibrocystic breast disease. J Mood Disord. 2016;6(4):230\u20133.","journal-title":"J Mood Disord"},{"key":"2547_CR37","volume-title":"Prevalence of hyperprolactinemia and hypothyroidism in benign breast disease in Government Rajaji Hospital, Madurai","author":"SK Rathlawath","year":"2017","unstructured":"Rathlawath SK. Prevalence of hyperprolactinemia and hypothyroidism in benign breast disease in Government Rajaji Hospital, Madurai. Madurai Medical College: Madurai; 2017."},{"issue":"3","key":"2547_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.37897\/RJMP.2016.3.7","volume":"11","author":"SD Artene","year":"2016","unstructured":"Artene SD, Bordea CI, Mircea D, Blidaru A. Beetroot and carrot juice increase the risk of thyroid nodules and hypothyroidism in breast cancer patients. Rom J Med Pract. 2016;11(3):251\u20136.","journal-title":"Rom J Med Pract."},{"issue":"1","key":"2547_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01337-z","volume":"22","author":"AM Falstie-Jensen","year":"2020","unstructured":"Falstie-Jensen AM, et al. Incidence of hypothyroidism after treatment for breast cancer\u2014a Danish matched cohort study. Breast Cancer Res. 2020;22(1):1\u201310.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"2547_CR40","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1089\/thy.2005.15.1253","volume":"15","author":"JL Kuijpens","year":"2005","unstructured":"Kuijpens JL, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005;15(11):1253\u20139.","journal-title":"Thyroid"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02547-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:12:36Z","timestamp":1647691956000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02547-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2547"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02547-5","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"16 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was confirmed by the Deputy of Research of Kurdistan University of Medical Sciences, Sanandaj, Iran.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}